Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Classical hematology 1

Conditions

Neoplasms 2Triple Negative Breast Neoplasms 1Thalassemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma 1Leukemia 1Anemia, Sickle Cell 1Anemia 1Adenocarcinoma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Erythrocyte Count × Clear all
NCT05255445 2024-05-17

RBC-IMPACT

Westat

Completed
157 enrolled
Classical hematology

Anemia, Sickle Cell, Neoplasms, Thalassemia

NCT02195180 2018-07-27

Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma

ERYtech Pharma

Phase 2 Completed
141 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡